期刊文献+

西地那非对肺动脉高压大鼠肺动脉压力影响的实验研究 被引量:3

Prevent and reverse effects of sildenafil on pulmonary hypertension in pneumonectomy combining to monocrotaline treated rats
下载PDF
导出
摘要 目的研究西地那非对肺动脉高压发生、发展的延缓及逆转作用,探讨其与内皮素系统的关系。方法单侧肺切除1周后叠加野百合碱60 mg.kg-1皮下注射建立肺动脉高压大鼠模型,在野百合碱注射后治疗组大鼠给予西地那非1.7 mg.kg-1.d-1,3周后测量大鼠平均肺动脉压(mPAP)、右心室重量与(左心室+室间隔)重量比值[RV/(LV+S)]、肺小血管管壁厚度与血管外径比值,免疫组织化学检测大鼠肺小血管壁平滑肌细胞内皮素-1A型受体(ETA-R)的表达,放射免疫法检测血浆内皮素-1浓度。结果治疗组大鼠mPAP、[RV/(LV+S)]、肺小血管管壁厚度与血管外径比值均低于对照组(P<0.05),肺小血管壁平滑肌细胞ETA-R的表达较对照组降低(P<0.05),血浆内皮素-1浓度较对照组升高,但无统计学意义。结论西地那非对单侧肺切除叠加野百合碱注射引起的肺动脉高压、右心室肥厚及肺血管结构重建具有良好的延缓和逆转作用。 Objective To investigate the protective and reverse effects of sildenafil on pulmonary hypertension in pneumonectomy combining to monocrotaline treated rats. Method The SD rats were randomly divided into the shamed-operation group, the control group and the treament group. All the rats were treated with monocrotaline (60 mg·kg^-1) one week after pneumonectomy. The treament group was treated with sidenafil ( 1.7 mg·kg^-1·d^-1 ) for 3 weeks. The mean pulmonary arterial pressure(mPAP) and right ventricle/left ven- tricle and septum [ RV/( LV + S) ] were measured and the small pulmonary arterial morphologic changes were observed with morphmetric analysis under microscopes. Immunohistochemistry was used to determine the expression of endothelin-1 A type receptor( ETA-R) on small pumlonary arterial and radioimmunity was used to determine the ET-1 level in plasma. Results The mPAP, [ RV/( LV + S) ], small pumlonary arterial morphologic changes were highly improved in sildenafil group( P〈0.05 ). The expression of ETA-R on small pumlonary arterial was significently reduced in treament group( P〈0.05 ). The ET-1 level in plasma was increased in treament group, but not reach the significant. Conclusion Sildenafil can prevent and reverse the development of pulmonary hypertension in pneumonectomy combining to monocrotaline treated rats.
出处 《现代医学》 2006年第3期154-157,共4页 Modern Medical Journal
关键词 西地那非 肺动脉高压 内皮素 内皮素受体 sildenafil pulmonary hypertension endothelin endothelial receotors
  • 相关文献

参考文献7

  • 1YANAGISAWA M,KURIHARA H,KIMURA S,et al.A novel potent vasoconstrictor peptide produced by vascular endothelial cells[J].Nature,1988,332(6163):411-415. 被引量:1
  • 2YUYAMA H,FUJIMORI A,SANAGI M,et al.The orally active nonpeptide selective endothelin ETA receptor antagonist YM598prevents and reverses the development of pulmonary hypertension in monocrotaline-treated rats[J].Eur J Pharmacol,2004,496(1-3):129-139. 被引量:1
  • 3TRACHTE A L,LOBATO E B,URDANETA F,et al.Oral sildenafil reduces pulmonary hyension after cardiac surgery[J].Ann Thorac Surg,2005,79 (1):194-197. 被引量:1
  • 4WILKINS M R,PAUL G A,STRANGE J W,et al.Sildenafil versus endothelin receptor antagonist for pulmonary hypertensionSERAPH) study[J].Am J Respir Crit Care Med,2005,171(11):1292-1297. 被引量:1
  • 5KATAOKA M,SATOH T,MANABE T,et al.Oral sildenafil improves primary pulmonary hypertension refractory to epoprostenol[J].Circ J,2005,69(4):461-465 被引量:1
  • 6LUSCHER T F,BARTON M.Endothelins and endothelin receptor antagonists:therapeutic considerations for a novel class of cardiovascular drugs[J].Circulation,2000,102 (19):2434-2440. 被引量:1
  • 7LYONS J M,DUFFY Y J,WAGNER J C,et al.Sildenafil citrate alleviates pulmonary hypertension after hypoxia and reoxygenation with cardiopulmonary bypass[J].J Am Coll Surg,2004,199(4):607-614. 被引量:1

同被引文献41

  • 1周华富.先心病肺动脉高压的治疗进展[J].广西医学,2005,27(12):1895-1897. 被引量:3
  • 2曾嵘,庄建,岑坚正.西地那非与前列腺素E_1治疗猪肺动脉高压[J].岭南心血管病杂志,2007,13(3):217-220. 被引量:5
  • 3Rubin LJ, Badeseh DB, Barst R J, et al. Bosentan therapy for pulmonary arterial hypertension [ J ]. N Engl J Med, 2006, 346 : 896 - 903. 被引量:1
  • 4Galie N, Hinderliter AL, Torbicki A, et al. Effects of the oral endothelin receptor antagonist bosentan on echocardiographic and Doppler measures in patients with pulmonary arterial hypertension[M]. American: Congress of Cardiology Atlanta, 2004 : 17 - 20. 被引量:1
  • 5Simmoneau G, Barst R, Gaffe N, et al. Continuous subcutaneousinfusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension [J]. Am J Respit Crit Care Med, 2005, 165:800 - 804. 被引量:1
  • 6Galie N, Humbert M, Wachiery JL, et al. Effects of beraprostsodium, an oral prostacyclin analogue, inpatients with pulmonary arterial hypertension: a randomized, double- blind, placebo- controlledtrial[J]. J Am Coll Cardiol, 2005, 39 : 1496 - 1502. 被引量:1
  • 7Fruhwald FM, Kjellstrom B, Perthold W, et al. Continuoushemodynamie monitoring in pulmonary hypertensive patients treated with inhaled iloprost[J]. Chest, 2005,124:351 - 359. 被引量:1
  • 8Wilkens H, Guth A, Konig J, et al. Effect of inhaled iloprost plus oral sildenafil in patients with primary pulmonary hypertension [J]. Cireulation, 2005, 104 : 1218 - 1229. 被引量:1
  • 9Kataoka M, Satoh T, Manabem T, et al. Oral sildenafil improves primary pulmonary hypertension refractory to epoprostenol [J]. Cire J, 2005, 69(4): 461-465. 被引量:1
  • 10Sebkhi A, Strange JW, Phillips SC, et al. Phosphodiesterase type 5 as a target for the treatment of hypoxia - induced pulmonary hypertension [J]. Circulation, 2003, 107:3230- 3235. 被引量:1

引证文献3

二级引证文献14

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部